Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia February 12, 2026 8:00 ...
Q4 2025 Earnings Call February 12, 2026 11:00 AM ESTCompany ParticipantsLiz Hunter - Vice President of Investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results